Literature DB >> 8982376

Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

S La Rosa1, F Sessa, C Capella, C Riva, B E Leone, C Klersy, G Rindi, E Solcia.   

Abstract

To identify prognostic subgroups among non-functioning (nonsyndromic) pancreatic endocrine tumours, a series of 61 tumours were analysed systematically for macroscopic, histopathological and immunohistochemical variables potentially predictive of malignancy. High-grade nuclear atypia, elevated mitotic rate and multifocal necrosis allowed us to separate 5 poorly differentiated carcinomas from 56 well differentiated tumours. Among the latter, 29 well-differentiated carcinomas showing gross local invasion or metastases were identified. Vascular or perineural microinvasion, Ki67 proliferative index > 2%, mitotic rate > or = 2, size > or = 4 cm, capsular penetration, nuclear atypia, lack of progesterone receptors and presence of calcitonin were among the variables correlated with malignancy. The first two were the most sensitive and specific. Their presence or absence was used in the 27 tumours lacking evidence of malignancy at the time of surgery to separate 11 cases with increased risk of malignancy (in 2 of which metastases developed during follow-up) from 16 cases with limited risk. The resulting four prognostic groups of non-functioning pancreatic endocrine tumours (limited- and increased-risk tumours, well-differentiated carcinomas and poorly differentiated carcinomas) showed distinct survival curves, which were significantly affected by vascular microinvasion, Ki67 proliferative index and metastases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982376     DOI: 10.1007/bf00198436

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

Review 1.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Pancreatic islet cell tumors.

Authors:  T A Broughan; J D Leslie; J M Soto; R E Hermann
Journal:  Surgery       Date:  1986-06       Impact factor: 3.982

3.  Pancreatic islet cell carcinoma. I. Clinical features of 52 patients.

Authors:  L E Broder; S K Carter
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Argyrophil organizer region proteins (AgNORs) in adenohypophysial cells and adenomas of the human pituitary.

Authors:  L Stefaneanu; E Horvath; K Kovacs
Journal:  Mod Pathol       Date:  1989-05       Impact factor: 7.842

Review 6.  Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

Authors:  E Ruttman; G Klöppel; G Bommer; M Kiehn; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

7.  Nonfunctioning islet cell tumors.

Authors:  R B Kent; J A van Heerden; L H Weiland
Journal:  Ann Surg       Date:  1981-02       Impact factor: 12.969

8.  Pancreatic polypeptide-producing tumors. Silent lesions of the pancreas?

Authors:  W E Strodel; A I Vinik; R V Lloyd; B Glaser; F E Eckhauser; R G Fiddian-Green; J G Turcotte; N W Thompson
Journal:  Arch Surg       Date:  1984-05

9.  Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.

Authors:  J R Goldblum; R Shannon; E P Kaldjian; M Thiny; R Davenport; N Thompson; R V Lloyd
Journal:  Mod Pathol       Date:  1993-11       Impact factor: 7.842

10.  Nonfunctioning pancreatic endocrine tumors. An immunohistochemical and electron microscopic analysis of 26 cases.

Authors:  T H Liu; Y Zhu; Q C Cui; L X Cai; S F Ye; S X Zhong; H P Jia
Journal:  Pathol Res Pract       Date:  1992-02       Impact factor: 3.250

View more
  43 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

3.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

4.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

5.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.

Authors:  L Tauchmanovà; M Pensabene; I Capuano; I Spagnoletti; P Zeppa; S Del Vecchio; M Mainenti; G De Rosa; A Colao; A Contegiacomo
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

7.  Multihormonality and entrapment of islets in pancreatic endocrine tumors.

Authors:  Y Kapran; J Bauersfeld; M Anlauf; B Sipos; G Klöppel
Journal:  Virchows Arch       Date:  2006-01-18       Impact factor: 4.064

8.  Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors:  Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal:  Virchows Arch       Date:  2015-09-17       Impact factor: 4.064

Review 9.  [Tumors of the endocrine pancreas].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

10.  Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.

Authors:  Ashlie Nadler; Moises Cukier; Corwyn Rowsell; Sepideh Kamali; Yael Feinberg; Simron Singh; Calvin H L Law
Journal:  Virchows Arch       Date:  2013-04-16       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.